Literature DB >> 21703370

The Sox2 high mobility group transcription factor inhibits mature osteoblast function in transgenic mice.

Greg Holmes1, Timothy G Bromage, Claudio Basilico.   

Abstract

We have previously shown that in osteoblasts Sox2 expression can be induced by Fgfs, and can inhibit Wnt signaling and differentiation. Furthermore, in mice in which Sox2 is conditionally deleted in the osteoblastic lineage, bones are osteopenic, and Sox2 inactivation in cultured osteoblasts leads to a loss of proliferative ability with a senescent phenotype. To help understand the role of Sox2 in osteoblast development we have specifically expressed Sox2 in bone from a Col1α1 promoter, which extended Sox2 expression into more mature osteoblasts. In long bones, trabecular cartilage remodeling was delayed and the transition from endochondral to cortical bone was disrupted, resulting in porous and undermineralized cortical bone. Collagen deposition was disorganized, and patterns of osteoclast activity were altered. Calvarial bones were thinner and parietal bones failed to develop the diploic space. Microarray analysis showed significant up- or downregulation of a variety of genes coding for non-collagenous extracellular matrix proteins, with a number of genes typical of mature osteoblasts being downregulated. Our results position Sox2 as a negative regulator of osteoblast maturation in vivo.
Copyright © 2011 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21703370      PMCID: PMC3167013          DOI: 10.1016/j.bone.2011.06.008

Source DB:  PubMed          Journal:  Bone        ISSN: 1873-2763            Impact factor:   4.398


  36 in total

Review 1.  Osteoclast differentiation and activation.

Authors:  William J Boyle; W Scott Simonet; David L Lacey
Journal:  Nature       Date:  2003-05-15       Impact factor: 49.962

2.  Cloning and sequence analysis of rat bone sialoprotein (osteopontin) cDNA reveals an Arg-Gly-Asp cell-binding sequence.

Authors:  A Oldberg; A Franzén; D Heinegård
Journal:  Proc Natl Acad Sci U S A       Date:  1986-12       Impact factor: 11.205

3.  Ameloblastin expression and putative autoregulation in mesenchymal cells suggest a role in early bone formation and repair.

Authors:  Margareth V Tamburstuen; Janne E Reseland; Axel Spahr; Steven J Brookes; Gunnar Kvalheim; Ivan Slaby; Malcolm L Snead; S Petter Lyngstadaas
Journal:  Bone       Date:  2010-09-18       Impact factor: 4.398

4.  Developmental-specific activity of the FGF-4 enhancer requires the synergistic action of Sox2 and Oct-3.

Authors:  H Yuan; N Corbi; C Basilico; L Dailey
Journal:  Genes Dev       Date:  1995-11-01       Impact factor: 11.361

5.  Impaired recruitment and differentiation of osteoclast progenitors by osteocalcin-deplete bone implants.

Authors:  J Glowacki; J B Lian
Journal:  Cell Differ       Date:  1987-09

6.  Tissue distribution and activity testing suggest a similar but not identical function of fetuin-B and fetuin-A.

Authors:  Bernd Denecke; Steffen Gräber; Cora Schäfer; Alexander Heiss; Michael Wöltje; Willi Jahnen-Dechent
Journal:  Biochem J       Date:  2003-11-15       Impact factor: 3.857

7.  Expression of interstitial collagenase during skeletal development of the mouse is restricted to osteoblast-like cells and hypertrophic chondrocytes.

Authors:  S Gack; R Vallon; J Schmidt; A Grigoriadis; J Tuckermann; J Schenkel; H Weiher; E F Wagner; P Angel
Journal:  Cell Growth Differ       Date:  1995-06

8.  A gene mapping to the sex-determining region of the mouse Y chromosome is a member of a novel family of embryonically expressed genes.

Authors:  J Gubbay; J Collignon; P Koopman; B Capel; A Economou; A Münsterberg; N Vivian; P Goodfellow; R Lovell-Badge
Journal:  Nature       Date:  1990-07-19       Impact factor: 49.962

9.  Separate cis-acting DNA elements of the mouse pro-alpha 1(I) collagen promoter direct expression of reporter genes to different type I collagen-producing cells in transgenic mice.

Authors:  J Rossert; H Eberspaecher; B de Crombrugghe
Journal:  J Cell Biol       Date:  1995-06       Impact factor: 10.539

10.  Sox2 deficiency causes neurodegeneration and impaired neurogenesis in the adult mouse brain.

Authors:  Anna L M Ferri; Maurizio Cavallaro; Daniela Braida; Antonello Di Cristofano; Annalisa Canta; Annamaria Vezzani; Sergio Ottolenghi; Pier Paolo Pandolfi; Mariaelvina Sala; Silvia DeBiasi; Silvia K Nicolis
Journal:  Development       Date:  2004-07-07       Impact factor: 6.868

View more
  6 in total

1.  Over-expression of Sox2 in C3H10T1/2 cells inhibits osteoblast differentiation through Wnt and MAPK signalling pathways.

Authors:  Daofang Ding; Hao Xu; Qianqian Liang; Leqin Xu; Yongjian Zhao; Yongjun Wang
Journal:  Int Orthop       Date:  2011-10-20       Impact factor: 3.075

Review 2.  The sox family of transcription factors: versatile regulators of stem and progenitor cell fate.

Authors:  Abby Sarkar; Konrad Hochedlinger
Journal:  Cell Stem Cell       Date:  2013-01-03       Impact factor: 24.633

3.  SOX2 regulates YAP1 to maintain stemness and determine cell fate in the osteo-adipo lineage.

Authors:  Eunjeong Seo; Upal Basu-Roy; Preethi H Gunaratne; Cristian Coarfa; Dae-Sik Lim; Claudio Basilico; Alka Mansukhani
Journal:  Cell Rep       Date:  2013-06-20       Impact factor: 9.423

Review 4.  Functional characterization of SOX2 as an anticancer target.

Authors:  Shizhen Zhang; Xiufang Xiong; Yi Sun
Journal:  Signal Transduct Target Ther       Date:  2020-07-29

5.  O-GlcNAcylation of Sox2 at threonine 258 regulates the self-renewal and early cell fate of embryonic stem cells.

Authors:  Dong Keon Kim; Jang-Seok Lee; Eun Young Lee; Hansol Jang; Suji Han; Hee Yeon Kim; In-Young Hwang; Ji-Woong Choi; Hyun Mu Shin; Hye Jin You; Hong-Duk Youn; Hyonchol Jang
Journal:  Exp Mol Med       Date:  2021-11-24       Impact factor: 8.718

6.  Role of hyaluronan in regulating self-renewal and osteogenic differentiation of mesenchymal stromal cells and pre-osteoblasts.

Authors:  Maria B Asparuhova; Vivianne Chappuis; Alexandra Stähli; Daniel Buser; Anton Sculean
Journal:  Clin Oral Investig       Date:  2020-03-31       Impact factor: 3.573

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.